Insulet Corporation (PODD) Position Maintained by Advisory Research Inc.

Advisory Research Inc. held its stake in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,061 shares of the medical instruments supplier’s stock at the end of the second quarter. Advisory Research Inc. owned 0.06% of Insulet Corporation worth $1,382,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of PODD. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Insulet Corporation by 11.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after buying an additional 235 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Insulet Corporation in the 2nd quarter valued at approximately $180,000. Teacher Retirement System of Texas bought a new stake in shares of Insulet Corporation in the 1st quarter valued at approximately $201,000. Diversified Trust Co bought a new stake in shares of Insulet Corporation in the 2nd quarter valued at approximately $205,000. Finally, Ameritas Investment Partners Inc. bought a new stake in shares of Insulet Corporation in the 1st quarter valued at approximately $215,000.

In other Insulet Corporation news, EVP Charles Alpuche bought 2,500 shares of Insulet Corporation stock in a transaction dated Wednesday, September 6th. The stock was bought at an average cost of $58.08 per share, for a total transaction of $145,200.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.90% of the company’s stock.

Several brokerages recently commented on PODD. Leerink Swann reissued an “outperform” rating and issued a $74.00 price target (up previously from $65.00) on shares of Insulet Corporation in a research note on Thursday. Zacks Investment Research raised Insulet Corporation from a “sell” rating to a “hold” rating in a research note on Thursday. Wedbush reissued a “buy” rating and issued a $65.00 price target (up previously from $60.00) on shares of Insulet Corporation in a research note on Tuesday. Canaccord Genuity reissued a “hold” rating and issued a $50.00 price target on shares of Insulet Corporation in a research note on Wednesday, September 27th. Finally, Barclays PLC began coverage on Insulet Corporation in a research note on Friday, September 15th. They issued an “overweight” rating and a $65.00 price target for the company. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $54.29.

Insulet Corporation (NASDAQ:PODD) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The company had revenue of $110.00 million during the quarter, compared to the consensus estimate of $106.23 million. During the same period in the previous year, the company posted ($0.08) EPS. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year.

WARNING: “Insulet Corporation (PODD) Position Maintained by Advisory Research Inc.” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://sportsperspectives.com/2017/10/13/insulet-corporation-podd-position-maintained-by-advisory-research-inc.html.

Insulet Corporation Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply